Cingulate Inc.

CING Nasdaq CIK: 0001862150

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 1901 W. 47TH PLACE, KANSAS CITY, KS, 66205
Mailing Address 1901 W. 47TH PLACE, KANSAS CITY, KS, 66205
Phone (913) 942-2300
Fiscal Year End 1231
EIN 863825535

Financial Overview

FY2024

$3.49M
Total Assets
$10.36M
Total Liabilities
$7.46M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
4 Insider stock transaction report February 10, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) February 9, 2026 View on SEC
8-K Current report of material events February 6, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
8-K Current report of material events January 15, 2026 View on SEC
S-3 Shelf registration for future offerings January 12, 2026 View on SEC
424B5 Prospectus supplement January 12, 2026 View on SEC

Material Events

8-K Leadership Change December 15, 2025
High Impact
  • Cingulate Inc. CEO Dr. Shane Schaffer has returned to his role after being on administrative leave since August.
  • Dr. Schaffer's leave was due to a personal legal matter, which is now resolved; he pleaded 'no contest' to a misdemeanor and received 12 months probation.
View Analysis

Insider Trading

BUY 4 insiders 4 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.